Treatment of Recurrent Adult Granulosa Cell Tumor

Immediate Management Priorities

• The American College of Obstetricians and Gynecologists recommends that surgical cytoreduction should be attempted whenever feasible for recurrent granulosa cell tumors, as it is the most effective treatment, especially in cases of early recurrence at 6 months, which suggests aggressive disease biology 1, 2, 3
• Early recurrence at 6 months indicates more aggressive tumor biology, making complete surgical debulking particularly critical for improving outcomes, with a goal of complete macroscopic resection 1, 2, 3

Treatment Algorithm

• The National Comprehensive Cancer Network recommends referring immediately to a gynecologic oncology center experienced in ovarian cancer surgery for evaluation of surgical candidacy, and performing complete debulking surgery to remove all gross tumor if technically feasible 1, 2, 3, 4
• The European Society for Medical Oncology suggests that after surgical cytoreduction, platinum-based chemotherapy with BEP (bleomycin, etoposide, cisplatin) for at least 3 cycles or carboplatin/paclitaxel for 6 cycles should be initiated, as these regimens have superior response rates 1, 2, 3

Monitoring During and After Treatment

• The American College of Obstetricians and Gynecologists recommends monitoring inhibin B levels every 2-4 months during the first 2 years, as it is the most sensitive and specific marker for granulosa cell tumors 1, 5, 6
• The Society of Gynecologic Oncology suggests performing CT scans of the abdomen, pelvis, and chest every 3-6 months for the first 2 years, and pelvic ultrasound every 6 months if fertility-sparing surgery was performed 1, 6

Long-Term Surveillance Considerations

• The National Comprehensive Cancer Network recommends lifelong follow-up, as granulosa cell tumors can recur up to 37 years after initial diagnosis, and continuing surveillance every 6 months beyond 5 years 1, 5, 6

Alternative Regimens for Chemotherapy-Resistant Disease

• The European Society for Medical Oncology suggests considering alternative regimens such as paclitaxel/ifosfamide/cisplatin (TIP), vincristine/dactinomycin/cyclophosphamide (VAC), or paclitaxel/gemcitabine for chemotherapy-resistant disease 7